Precipio, Inc. (PRPO): Results of Operations and Financial Condition
Precipio, Inc. (PRPO) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 tm2623274d1_ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 Precipio Announces Q2-2026 Financial Results Revenue reaches quarterly record as Precipio returns to positive Adjusted EBITDA and strengthens cash position NEW HAVEN, CT, Globenewswire – (Aug 14, 2026) - Specialty cancer
How this was made
The 30-second read
Why it matters
The newest actionable information is the Q2-2026 operating recovery: quarterly revenue above $7M for the first time in company history, Adjusted EBITDA turning positive, and cash balance exceeding $3M without a financing event.
Market read
For PRPO, the combination of revenue growth, positive Adjusted EBITDA, and higher cash balance is a near-term re-rating catalyst, with follow-through dependent on details to be provided in the Aug 17 call and the filed 10-Q.
What to watch
The release references a more in-depth discussion in the Aug 17 call and a same-day 10-Q; traders may need to verify revenue quality, burn rate trajectory, and any working-capital swings that could reverse cash trends.
Background
This is an SEC 8-K (Item 2.02) attaching Q2-2026 financial results and noting a shareholder call on Aug 17, 2026.
Ticker impact
Precipio reported Q2-2026 revenue of $7.0M, Adjusted EBITDA of $0.4M, and cash above $3M, signaling an operating recovery.
Likely positive bias for the next session and into the Aug 17 shareholder call, with volatility tied to any guidance or margin/cash-flow follow-through.
The filing is a primary disclosure (8-K with earnings metrics) and includes multiple directionally favorable datapoints (revenue growth, EBITDA improvement, cash balance). However, the text does not provide full guidance or segment detail beyond high-level revenue categories, limiting conviction on sustainability.
Market effects
Supports sentiment for small-cap specialty cancer diagnostics by demonstrating operating leverage and cash improvement, though impact is likely company-specific.
Limited, as the disclosure is for a single US-listed micro/small-cap issuer.
Low, no cross-border deal, regulatory action, or sector-wide catalyst mentioned.
Counterpoint
Adjusted EBITDA improvement may be partly driven by non-recurring or accounting effects (e.g., stock-based compensation changes), so investors may discount sustainability until additional quarters confirm margins and cash conversion.
Key entities
- companyPrecipio, Inc.
Specialty cancer diagnostics company reporting Q2-2026 financial results on Form 8-K.
- executiveIl an Danieli
CEO quoted on operating momentum and cash strength.
